PECAM1 and neoplasm: Immunohistochemical studies further revealed that TPL and ATF combined treatment markedly reduced the expression of CD31, a marker of neoangiogenesis (Figure 7G and 7H), suggesting that combination of TPL and ATF could inhibit tumour progression primarily through suppressing tumour-related angiogenesis.